Rusan Pharma is a fully integrated global pharmaceutical corporation specializing in addiction treatment and pain management. The company manufactures and markets a diverse range of API and finished formulations, particularly focusing on controlled (narcotic and psychotropic) substances. Rusan's facilities hold GMP approval from Health Canada, EU, TGA, ANVISA, PIC/S, WHO, Russia, and SAHPRA. Additionally, Rusan has CEP approval for various APIs including Buprenorphine, Fentanyl, Naltrexone, Methadone, Bisoprolol, and also produces Naloxone, Nalbuphine, Nalmefene, Apomorphine, Efflornithine, and Sodium Oxybate. The company also develops and manufactures a variety of transdermal patches and long-acting formulations such as depot injections and implants.